Sweet Ping Ng1, Jason M Johnson2, G Brandon Gunn1, David I Rosenthal1, Heath D Skinner1, Jack Phan1, Steven J Frank1, William Morrison1, Erich M Sturgis3, Frank E Mott4, Michelle D Williams5, Clifton D Fuller1, Adam S Garden6. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: agarden@mdanderson.org.
Abstract
PURPOSE: Patients with p16/human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma have a favorable outcome after treatment. In this group of patients who could have a long life expectancy, the optimal surveillance strategy and modality is not well established. We aim to determine the ability of a negative postradiation positron emission tomography (PET)/computed tomography scan to predict the risk of subsequent relapse in these patients. MATERIALS AND METHODS: A retrospective analysis of patients with p16/HPV-associated oropharyngeal squamous cell carcinoma who completed definitive (chemo)radiation therapy and had a posttreatment PET/computed tomography scan from 2006 to 2013 was performed. Patient, tumor, and treatment characteristics and clinical outcomes were recorded. Tumors were considered HPV/p16 positive if either HPV (by in situ hybridization) or p16 (by immunohistochemistry) was positive. Disease-free survival and overall survival rates were estimated using the Kaplan-Meier method. RESULTS: In our study, 327 patients were evaluated. The median age was 57 years. The most common primary sites were base of tongue (50%) and tonsil (48%). Of the patients evaluated, 291 (89%) had a negative posttreatment PET scan. For these 291 patients who had a complete metabolic response after treatment, the 5-year disease-free survival and overall survival rates were 91% and 89%, respectively. The median time to development of recurrence was 16 months. Of the 291 patients, 24 patients (8%) had disease recurrence; 13 recurrences were locoregional, and 13 were distant. Eleven (4%) patients with recurrence had further surgery or radiation, and 8 patients (3%) were without disease as of the last follow-up. CONCLUSIONS: Patients who achieve a complete metabolic response on posttreatment PET imaging have an excellent prognosis, and the risk of developing a recurrence in the future is very low. Therefore, a more cost effective surveillance program should be considered for this subgroup of patients.
PURPOSE:Patients with p16/human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma have a favorable outcome after treatment. In this group of patients who could have a long life expectancy, the optimal surveillance strategy and modality is not well established. We aim to determine the ability of a negative postradiation positron emission tomography (PET)/computed tomography scan to predict the risk of subsequent relapse in these patients. MATERIALS AND METHODS: A retrospective analysis of patients with p16/HPV-associated oropharyngeal squamous cell carcinoma who completed definitive (chemo)radiation therapy and had a posttreatment PET/computed tomography scan from 2006 to 2013 was performed. Patient, tumor, and treatment characteristics and clinical outcomes were recorded. Tumors were considered HPV/p16 positive if either HPV (by in situ hybridization) or p16 (by immunohistochemistry) was positive. Disease-free survival and overall survival rates were estimated using the Kaplan-Meier method. RESULTS: In our study, 327 patients were evaluated. The median age was 57 years. The most common primary sites were base of tongue (50%) and tonsil (48%). Of the patients evaluated, 291 (89%) had a negative posttreatment PET scan. For these 291 patients who had a complete metabolic response after treatment, the 5-year disease-free survival and overall survival rates were 91% and 89%, respectively. The median time to development of recurrence was 16 months. Of the 291 patients, 24 patients (8%) had disease recurrence; 13 recurrences were locoregional, and 13 were distant. Eleven (4%) patients with recurrence had further surgery or radiation, and 8 patients (3%) were without disease as of the last follow-up. CONCLUSIONS:Patients who achieve a complete metabolic response on posttreatment PET imaging have an excellent prognosis, and the risk of developing a recurrence in the future is very low. Therefore, a more cost effective surveillance program should be considered for this subgroup of patients.
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Travis C Salzillo; Nicolette Taku; Kareem A Wahid; Brigid A McDonald; Jarey Wang; Lisanne V van Dijk; Jillian M Rigert; Abdallah S R Mohamed; Jihong Wang; Stephen Y Lai; Clifton D Fuller Journal: Semin Radiat Oncol Date: 2021-10 Impact factor: 5.421
Authors: Zsuzsanna Iyizoba-Ebozue; Sarah Billingsley; Russell Frood; Sriram Vaidyanathan; Andrew Scarsbrook; Robin J D Prestwich Journal: Cancers (Basel) Date: 2022-09-26 Impact factor: 6.575
Authors: Houda Bahig; Ying Yuan; Abdallah S R Mohamed; Kristy K Brock; Sweet Ping Ng; Jihong Wang; Yao Ding; Kate Hutcheson; Molly McCulloch; Peter A Balter; Stephen Y Lai; Abrahim Al-Mamgani; Jan-Jakob Sonke; Uulke A van der Heide; Christopher Nutting; X Allen Li; Jared Robbins; Mussadiq Awan; Irene Karam; Katherine Newbold; Kevin Harrington; Uwe Oelfke; Shreerang Bhide; Marielle E P Philippens; Chris H J Terhaard; Andrew J McPartlin; Pierre Blanchard; Adam S Garden; David I Rosenthal; Gary B Gunn; Jack Phan; Guillaume Cazoulat; Michalis Aristophanous; Kelli K McSpadden; John A Garcia; Cornelis A T van den Berg; Cornelis P J Raaijmakers; Linda Kerkmeijer; Patricia Doornaert; Sanne Blinde; Steven J Frank; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2018-08-24